Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
J Investig Med ; 69(6): 1153-1155, 2021 08.
Article in English | MEDLINE | ID: covidwho-1247390

ABSTRACT

Venous thromboembolism associated with COVID-19, particularly acute pulmonary embolism, may represent a challenging and complex clinical scenario. The benefits of having a multidisciplinary pulmonary embolism response team (PERT) can be important during such a pandemic. The aim of PERT in the care of such patients is to provide fast, appropriate, multidisciplinary, team-based approach, with the common goal to tailor the best therapeutic decision making, prioritizing always optimal patient care, especially given lack of evidence-based clinical practice guidelines in the setting of COVID-19, which potentially confers a significant prothrombotic state. Herein, we would like to briefly emphasize the importance and potential critical role of PERT in the care of patients in which these two devastating illnesses are present together.


Subject(s)
COVID-19/therapy , Pulmonary Embolism/therapy , Thromboembolism/therapy , Venous Thromboembolism/therapy , Acute Disease , Anticoagulants/therapeutic use , COVID-19/complications , Cardiology/organization & administration , Decision Making , Evidence-Based Medicine , Humans , Interdisciplinary Communication , Practice Guidelines as Topic , Pulmonary Embolism/complications , Pulmonary Medicine/organization & administration , Quality of Life , SARS-CoV-2 , Thromboembolism/complications , Thrombolytic Therapy , Treatment Outcome , Venous Thromboembolism/complications
2.
Respir Investig ; 59(4): 385-388, 2021 Jul.
Article in English | MEDLINE | ID: covidwho-1203265

ABSTRACT

The Japanese Respiratory Society (JRS) has recommended spirometry for the diagnosis of respiratory diseases. It is indispensable for the confirmation of airflow obstruction by spirometry in chronic obstructive pulmonary disease (COPD) diagnosis. However, the coronavirus disease 2019 (COVID-19) pandemic has made it difficult for many clinics to perform spirometry as it may lead to possible aerosol infections. Thus, the diagnosis of COPD, especially in the early stage, has become difficult. To overcome this situation, JRS issued a "Flowchart of Working Diagnosis and Management of COPD during the COVID-19 Pandemic". This flowchart may help physicians provisionally diagnose COPD patients without performing spirometry, offering them appropriate intervention even in epidemic and pandemic situations.


Subject(s)
COVID-19 , Diagnostic Techniques, Respiratory System , Pulmonary Disease, Chronic Obstructive/diagnosis , Pulmonary Disease, Chronic Obstructive/therapy , Pulmonary Medicine/organization & administration , Societies, Medical/organization & administration , Adrenergic beta-2 Receptor Agonists/therapeutic use , Delayed-Action Preparations , Drug Therapy, Combination , Early Diagnosis , Humans , Japan , Muscarinic Antagonists/therapeutic use , Spirometry
4.
Eur Respir J ; 57(3)2021 03.
Article in English | MEDLINE | ID: covidwho-937059

ABSTRACT

Clinical activities regarding sleep disordered breathing (SDB) have been sharply interrupted during the initial phase of the coronavirus disease 2019 (COVID-19) epidemic throughout Europe. In the past months, activities have gradually restarted, according to epidemiological phase of COVID-19 and national recommendations. The recent increase in cases throughout Europe demands a reconsideration of management strategies of SDB accordingly. Diagnosis of SDB and initiation of treatment pose some specific problems to be addressed to preserve the safety of patients and health personnel. This perspective document by a group of European sleep experts aims to summarise some different approaches followed in Europe and United States, which reflect national recommendations according to the epidemiological phase of the COVID-19 infection. Respiratory sleep medicine is likely to change in the near future, and use of telemedicine will grow to avoid unnecessary risks and continue to provide optimal care to patients. In addition, the document covers paediatric sleep studies and indications for titration of noninvasive ventilation, as well as precautions to be followed by patients who are already on positive airway pressure treatment. A single consensus document developed by the European Respiratory Society and national societies would be desirable to harmonise SDB management throughout Europe.


Subject(s)
COVID-19 , Laboratories/organization & administration , Pulmonary Medicine/organization & administration , Sleep Apnea Syndromes/diagnosis , COVID-19/epidemiology , Europe/epidemiology , Humans
7.
Respir Med Res ; 78: 100768, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-668677

ABSTRACT

With first cases noted towards the end of 2019 in China, COVID-19 infection was rapidly become a devastating pandemic. Even if most patients present with a mild to moderate form of the disease, the estimated prevalence of COVID-19-related severe acute respiratory failure (ARF) is 15-20% and 2-12% needed intubation and mechanical ventilation. In addition to mechanical ventilation some other techniques of respiratory support could be used in some forms of COVID-19 related ARF. This position paper of the Respiratory Support and Chronic Care Group of the French Society of Respiratory Diseases is intended to help respiratory clinicians involved in care of COVID-19 pandemic in the rational use of non-invasive techniques such as oxygen therapy, CPAP, non-invasive ventilation and high flow oxygen therapy in managing patients outside intensive care unit (ICU). The aims are: (1) to focus both on the place of each technique and in describing practical tips (types of devices and circuit assemblies) aimed to limit the risk of caregivers when using those techniques at high risk spreading of viral particles; (2) to propose a step-by-step strategy to manage ARF outside ICU.


Subject(s)
COVID-19/epidemiology , COVID-19/therapy , Emergency Medical Services/standards , Oxygen Inhalation Therapy/standards , Pulmonary Medicine/standards , Respiration Disorders/therapy , Acute Disease , COVID-19/complications , COVID-19/pathology , Chronic Disease , Continuous Positive Airway Pressure/methods , Continuous Positive Airway Pressure/standards , Critical Care/methods , Critical Care/standards , Emergency Medical Services/methods , France/epidemiology , Humans , Intensive Care Units/standards , Nebulizers and Vaporizers/standards , Oxygen Inhalation Therapy/methods , Pandemics , Pulmonary Medicine/methods , Pulmonary Medicine/organization & administration , Respiration Disorders/epidemiology , Respiration Disorders/etiology , Respiration Disorders/pathology , Respiration, Artificial/methods , Respiration, Artificial/standards , Respiratory Distress Syndrome/epidemiology , Respiratory Distress Syndrome/etiology , Respiratory Distress Syndrome/pathology , Respiratory Distress Syndrome/therapy , Severity of Illness Index , Societies, Medical/standards
11.
Respir Med Res ; 78: 100769, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-343140

ABSTRACT

The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels.


Subject(s)
COVID-19/epidemiology , COVID-19/prevention & control , Pandemics , Thoracic Neoplasms/therapy , Antineoplastic Agents/therapeutic use , COVID-19/complications , Chemoradiotherapy/methods , Chemoradiotherapy/standards , Clinical Trials as Topic/methods , Clinical Trials as Topic/organization & administration , Clinical Trials as Topic/standards , Humans , Mutation , Neoadjuvant Therapy/methods , Neoadjuvant Therapy/standards , Neoplasm Metastasis , Pulmonary Medicine/methods , Pulmonary Medicine/organization & administration , Pulmonary Medicine/standards , Risk Factors , Risk Reduction Behavior , SARS-CoV-2 , Thoracic Neoplasms/epidemiology , Thoracic Neoplasms/genetics , Thoracic Neoplasms/pathology , Thoracic Surgical Procedures/methods , Thoracic Surgical Procedures/standards
SELECTION OF CITATIONS
SEARCH DETAIL
...